Press Release1 week agoDemeRx Strengthens Leadership Team With Appointment of Biopharmaceutical Executive Michael Snitkovsky as Chief Operations Officer
News beats1 week agoDemeRx Appoints Michael Snitkovsky as Chief Operating Officer to Advance Clinical Pipeline
News beats4 weeks agoDemeRx Announces FDA Acceptance of IND Application to Advance DMX-1001 for the Treatment of Alcohol Use Disorder (AUD)
Press Release6 months agoDemeRx Announces Successful Completion of Multiple Ascending Dose Clinical Trial of DMX-1001 for the Treatment of Alcohol Use Disorder (AUD)
Press Release1 year agoDemeRx Joins Medical Psychedelics Working Group to Advance Next-Generation Addiction Treatments
News beats2 years agoIbogaine and Noribogaine: Mechanisms and Therapeutic Potential as Addiction Medicines
News beats2 years agoThe Unparalleled Power of Ibogaine in Addiction Recovery With Tom Feegel, CEO of Beond
News beats2 years agoPowerful Psychedelic Gains Renewed Attention as a Treatment for Opioid Addiction
News beats2 years agoPsychedelics Today Ep. 448: Deborah C. Mash, Ph.D. – Ibogaine, Noribogaine, and the Challenges of Federal Drug Policy
News beats2 years agoOpium Addiction Market expected to rise – BioCorRx Inc, Delpor Inc, DemeRx Inc, Alar Pharmaceuticals, expected to drive market
News beats2 years agoAdvocates of using psychedelic drug ibogaine to treat addiction say its risks to the heart can be mitigated in a controlled study
News beats2 years agoKentucky’s $42 million allocation for psychedelics research for opioid addiction
News beats2 years agoDr. Deborah Mash on Why Ibogaine Treatment Aftercare is Key to Treating the Roots of Addiction
